Newsroom

Absci 3d ago

Dermatology Times recently highlighted our lead candidate, ABS-201, in treating pattern hair loss. The interim results from our Phase 1/2a clinical trial underscore the potential of ABS-201 by demonstrating a favorable preliminary safety profile and encouraging pharmacokinetic characteristics. Read the full article here: https://lnkd.in/gzxdzC7u Key takeaways from the article include: ⚫ Favorable Safety Profile: Single-ascending-dose IV ABS-201 (150–1800 mg) in 32 volunteers produced no serious adverse events. Treatment-emergent adverse events were predominantly mild, with headache being the most frequent. ⚫ Pharmacokinetic Data: PK data indicates a prolonged half-life of ≥65 days. These results support the potential for dosing two to three times over a six month period. ⚫ Immunogenicity: No apparent impact of anti-drug antibodies (ADAs) on PK was observed based on interim data in the SAD cohorts.

View post on LinkedIn

Absci 4d ago

Dermatology Times recently highlighted our lead candidate, ABS-201, in treating pattern hair loss. The interim results from our Phase 1/2a clinical trial underscore the potential of ABS-201 by demonstrating a favorable preliminary safety profile and encouraging pharmacokinetic characteristics Key takeaways from the article include: ⚫ Favorable Safety Profile: Single-ascending-dose IV ABS-201 (150–1800 mg) in 32 volunteers produced no serious adverse events. Treatment-emergent adverse events were predominantly mild, with headache being the most frequent. ⚫ Pharmacokinetic Data: PK data indicates a prolonged half-life of ≥65 days. These results support the potential for disoing two to three times over a six month period. ⚫ Immunogenicity: No apparent impact of anti-drug antibodies (ADAs) on PK was observed based on interim data in the SAD cohorts. Read the full article here: https://lnkd.in/gzxdzC7u

View post on LinkedIn

Absci 5d ago

Absci is pleased to welcome Dr. Axel Haupt to our Endometriosis Advisory Board. As SVP of Clinical Investigation, Diabetes, Obesity & Complications at Eli Lilly and Company, Dr. Haupt brings deep clinical expertise that will strengthen our mission to advance ABS-201 for patients living with endometriosis.

View post on LinkedIn